Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease

Launched by TOKYO MEDICAL AND DENTAL UNIVERSITY · Jan 4, 2015

Keywords

ClinConnect Summary

This clinical trial, called the Therapeutic Optimization Study, is looking at how different treatment approaches can help patients with Crohn's Disease, a condition that causes inflammation in the digestive system. Specifically, the study is examining what happens when patients who are currently in remission (feeling well) receive a stronger treatment option versus those who have achieved both clinical and imaging remission (both feeling well and showing no signs of disease on scans) and receive a reduced treatment. The main goal is to see how many patients remain in remission after two years of following these different treatment plans.

To participate in this study, you need to have a confirmed diagnosis of Crohn's Disease and be in clinical remission, meaning your symptoms are mild. You also need to be 18 years or older, or if you're younger, your guardian will need to give consent. Some people may not be eligible, such as those who can't take certain medications or have had recent surgeries. If you join the study, you'll receive treatment based on your current health status and be monitored closely over the next two years to see how you respond. This trial is currently active but not recruiting new participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of Crohn's and proven history of disease with clinical remission (CDAI\<150)
• • Signed written consent form to enroll the study (Need agreement from deputy for patients under 20years old)
• Exclusion Criteria:
• • Contraindication for infliximab, adalimumab, or azathioprine
• • Lactating woman
• • Presence of malignancy
• • Within 3 month from intestinal surgery
• • Presence of an end stoma
• • Planned surgery